New and existing pharmacotherapeutic options for persistent asthma and COPD

Netherlands Journal of Medicine

Volumn 69, Issue 11, 2011, Pages 486-499

  Diamant, Z ^a,b   Tarasevych, S ^c   Clarke, G W ^d,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^d GUY S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti cytokines; Anti IgE; Anticholinergics; Asthma; Beta2 agonists; COPD; Inhaled corticosteroids; Leukotriene modulators; PDE inhibitors; Pharmacotherapy; Xanthines

Indexed keywords

ADOAIR; AMINOPHYLLINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CARBUTEROL; CARMOTEROL; CICLESONIDE; CLENBUTEROL; CORTICOSTEROID; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FOSTER; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN E; INDACATEROL; IPRAMOL; IPRAPROPIUM; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; IPRAXA; MEPOLIZUMAB; MILVETEROL; MONTELUKAST; OLODATEROL; OMALIZUMAB; ONBREZ; REVOLAIR; ROFLUMILAST; SALBUTAMOL; SALBUTAMOL FNA; SALMETEROL; THEOBROMINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL TRIFENATATE; ZAFIRLUKAST; ZILEUTON;

ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CATARACT; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; COMORBIDITY; DIARRHEA; DISEASE EXACERBATION; DOWN REGULATION; DRUG CHOICE; DRUG EFFICACY; DYSPHONIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HOARSENESS; HUMAN; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMPHYSEMA; LUNG FUNCTION; MAINTENANCE THERAPY; METERED DOSE INHALER; MONOTHERAPY; NAUSEA; NOCTURNAL ASTHMA; ORAL CANDIDIASISS; OSTEOPENIA; OXIDATIVE STRESS; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; QUALITY OF LIFE; REVIEW; SEIZURE; SIDE EFFECT; SKIN BRUISING; SMOKING; URINE RETENTION; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 83755225546     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Global Initiative for Asthma (updated 2010), www.ginasthma.com.
2. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40-7.
3. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma control study. Am J Resp Crit Care Med. 2004;170:836-44.
4. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31(2):320-5.
5. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.
6. Global Initiative for Chronic Obstructive Lung Disease (updated 2010); www.goldcopd.com.
7. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.
8. de Marco, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004;59:120-5.
9. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875-81.
10. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589):741-50.
11. Barnes, P. J. Chronic obstructive pulmonary disease: a growing but neglected epidemic. PLoS Med. 2007;4(5):e112.
12. Mannino, DM, Buist, AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-73.
13. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet. 2003;62(9389):1053-61.
14. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804-13.
15. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3):531-9.
16. Cazzola M, Novelli G. Biomarkers in COPD. Pulm Pharmacol Ther. 2010;23(6):493-500.
17. Diamant Z, Boot JD, Mantzouranis E, Flohr R, Sterk PJ, Gerth van Wijk R. Biomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther. 2010;23(6):468-81.
18. Shirtcliffe P, Weatherall M, Travers J, Beasley R. The multiple dimensions of airways disease: targeting treatment to clinical phenotypes. Curr Opin Pulm Med. 2011;17(2):72-8.
19. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113(1):101-8.
20. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009 Apr;33(4):897-906.
21. Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011;127(6):1486-93. e2.
22. Holgate ST. Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches? J Allergy Clin Immunol. 2011 Jul 30. [Epub ahead of print].
23. Bjermer L. Targeting small airways, a step further in asthma management. Clin Respir J. 2011;5(3):131-5.
24. Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefält JS. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol. 2011;127(4):905-12.e1-7.
25. Lethbridge MW, Kemeny DM, Ratoff JC, O'Connor BJ, Hawrylowicz CM, Corrigan CJ. A novel technique to explore the functions of bronchial mucosal T cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity. Clin Exp Immunol. 2010;161(3):560-9.
26. Majo J, Ghezzo H, Cosio M. G. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17(5):946-53.
27. Saetta M, Baraldo S, Turato G, et al. Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):28-32.
28. Freeman CM, Han MK, Matrinez FJ, et al. Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. J Immunol. 2010;184(11):6504-13.
29. Hogg J, Chu F, Utokaparch S, et al. The nature of small airway obstruction in chronic obstructive lung disease. N Engl J Med. 2004;350:2645-53.
30. Broide DH, Finkelman F, Bochner BS, Rothenberg ME. Advances in mechanisms of asthma, allergy, and immunology in 2010. J Allergy Clin Immunol. 2011 Mar;127(3):689-95.
31. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010;26(3):466-76.
32. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470-7.
33. Kaminsky DA, Irvin CG, Sterk PJ. Complex systems in pulmonary medicine: a systems biology approach to lung disease. J Appl Physiol. 2011;110(6):1716-22.
34. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol. 1999;103:232-7.
35. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011 May 27. [Epub ahead of print].
36. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
37. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(10 Pt 2):S28-38.
38. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res. 2010;11:132.
39. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11:36.
40. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med. 2011 Aug;105(8):1118-28.
41. Spruit MA, Pennings HJ, Janssen PP, et al. Extra-pulmonary features in COPD patients entering rehabilitation after stratification for MRC dyspnea grade. Respir Med. 2007;101:2454-63.
42. Eisner MD, Iribarren C, Blanc PD, et al. Development of disability in chronic obstructive pulmonary disease: beyond lung function. Thorax. 2011;66(2):108-14.
43. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30-8.
44. Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-26.
45. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533(1-3):36-9.
46. Peters SP, Kunselman SJ, Icitovic MA, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715-26.
47. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315-22.
48. Gross NJ. Tiotropium bromide. Chest. 2004;126:1946-53.
49. Flynn RA, Glynn DA, Kennedy MP. Anticholinergic treatment in airway diseases. Adv Ther. 2009;26(10):908-19.
50. Tashkin DP, Celli B, Senn S, et al. A four year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
51. Ray NC, Alcaraz L. Muscarinic antagonist -beta-adrenergic agonist dual pharmacology molecules as bronchodilatators: a patient review. Expert Opin Ther Patients. 2009;19:1-12.
52. Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs. 2010;70(17):2269-80.
53. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
54. Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta (2) agonist, assessed in airway biopsies and bronchoalveolar lavage in astma. Am J Respir Crit Care Med. 1999;160(5Pt1):1493-9.
55. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J. 2003;21(6):994-9.
56. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158(3):924-30.
57. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336(8728):1391-6.
58. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adreno-ceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327(17):1198-203.
59. Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med. 2005;99(5):566-71.
60. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax. 2001;56(7):529-35.
61. van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther. 2003;16(3):153-61.
62. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118(4):809-16.
63. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotypestratified, randomised, placebo-con-trolled cross-over trial. Lancet. 2004;364(9444):1505-12.
64. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The salmeterol multicenter asthma research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
65. Terr AI, Bloch DA. Trends in asthma therapy in the United States: 1965-1992. Ann Allergy Asthma Immunol. 1996;76(3):273-81.
66. Barnes PJ. Current therapies for asthma. Promise and limitations. Chest. 1997;111(2):17S-26S.
67. Howell RE, Muehsam WT, Kinnier WJ. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci. 1990;46:563-8.
68. British guideline on the management of asthma. Thorax. 2003;58(Suppl1): i1-94.
69. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med. 1998;92(2):256-63.
70. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol. 1998;101(1,Part 1):14-23.
71. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003;167(6):813-8.
72. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J. 1995;8(6):996-1000.
73. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. PNAS 2002;99(13):8921-6.
74. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997;337(20):1412-8.
75. Ukena D, Harnest U, Sakalauskas R, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10(12):2754-60.
76. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest. 1997;100(7):1677-84.
77. Nickels TJ, Schwartz AD, Blevins DE, Drummond JT, Reed GW, Wilson DF. Effect of theophylline and aminophylline on transmitter release at the mammalian neuromuscular junction is not mediated by cAMP. Clin Exp Pharmacol Physiol. 2006;33(5-6):465-70.
78. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(7):897-904.
79. Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther. 2011;24(4):353-60.
80. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effects of intravenous olprinone, a phos-phodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol. 2003;55(4):341-6.
81. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972;1(5800):585-90.
82. Clark TJ. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet 1972;1(7765):1361-4.
83. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med. 2002;96(Suppl 1):S9-15.
84. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533 (1-3):2-14.
85. Yeadon M, Diamant Z. New and exploratory therapeutic agents for asthma, 1st ed. New York: Marcel Dekker; 2000.
86. Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. C linical c ontrol a nd h istopathologic o utcome o f a sthma w hen using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159(4, Part 1):1043-51.
87. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. 2009 Sep; 65(9):853-71.
88. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):76-85.
89. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834-43.
90. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M; TIPHON study group. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(2):301-10.
91. Hasegawa M, Makita H, Nasuhara Y, et al. Relationship between improved airflow limitation and changes in airway caliber induced by inhaled anticholinergics in chronic obstructive pulmonary disease. Thorax. 2009;64:332-8.
92. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
93. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-20.
94. Vincken W, van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19(2):209-16.
95. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68:1975-2000.
96. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007;356:775-89.
97. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: Results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-38.
98. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151(8):517-27.
99. Snoeck-Stroband JB, Lapperre TS, Gosman MM, et al. Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J. 2008;31(1):70-7.
100. Korenblat PE. Ciclesonide and the treatment of asthma. Expert Opin Pharmacother. 2010;11(3):463-79.
101. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother. 2006;7(15):2107-17.
102. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: a double-blind, placebo-controlled study. Respirology. 2007;12(4):566-72.
103. Nathan RA, Kanter L, Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. Allergy Asthma Proc. 2008;29(5):521-7.
104. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(2):CD002991.
105. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A. Use of inhaled corticosteroids and the risk of fracture. Chest. 2006; 130:1082-8.
106. Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoiddependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008;73(1):203-14.
107. Perttunen H, Moilanen E, Zhang X, Barnes PJ, Kankaanranta H. Beta2-agonists potentiate corticosteroid-induced neutrophil survival. COPD. 2008;5(3):163-9.
108. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Editorial. Clin Exp Allergy. 1999;29:1449-53.
109. Diamant Z, Mantzouranis E, Bjermer L. Expert review of montelukast in the treatment of asthma and beyond. Exp Rev Clin Immunol. 2009; 5(6);639-58.
110. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Review. Respir Med. 2007;101(3):378-88.
111. Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest. 2002;121(3):732-8.
112. Suppli Ulrik C, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing, Clin Exp Allergy. 2010;40: 576-81.
113. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011 5;364(18):1695-707.
114. Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy. 2006;61(6):737-42.
115. Virchow JC, Mehta A, Ljungblad L, Mitfessel H; MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010;104(5):644-51.
116. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010;47(9):986-93.
117. Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, Global Initiative for Asthma (GINA) 2009. Available from: http://www.ginasthma.org.
118. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007;61(4):663-76.
119. Sampson AP. FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009;10(11):1163-72.
120. Bain G, King CD, Rewolinski M, et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin Pharmacol Ther. 2010;87(4):437-44.
121. Maciolek CM, Ma B, Menzel K, et al. Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2011;39(5):763-70.
122. Bernstein JA, Liu N, Knorr BA, et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med. 2011;105(3):392-401.
123. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006;533(1-3):110-7.
124. Diamant Z. Spina D. PDE4-inhibitors: a novel targeted therapy for obstructive airways disease. Pulm Pharmacol Ther. 2011;24(4):353-60.
125. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53-67.
126. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154-61.
127. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
128. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-94.
129. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
130. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010;120(2-3):76-85.
131. Hirota K, Yoshioka H, Kabara S, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. PNAS. 2002;99(13):8921-6.
132. Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157(6):892-906.
133. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728-36.
134. Jansen DF, Rijcken B, Schouten JP, et al. The relationship of skin test positivity, high serum total IgE levels, and peripheral blood eosinophilia to symptomatic and asymptomatic airway hyperresponsiveness. Am J Respir Crit Care Med. 1999;159(3):924-31.
135. Di Domenico M, Bisogno A, Polverino M, De Rosa C, Ricci V, Capasso A. Xolair in asthma therapy: an overview. Inflamm Allergy Drug Targets. 2011;10(1):2-12.
136. Morjaria JB, Polosa R. Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Rev Respir Med. 2009;3(3):299-308.
137. Kim HL, Leigh R, Becker A. Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol. 2010;6(1):32.
138. Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011 24;7(1):9.
139. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011;127(1):8-15.
140. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008 November 3;118(11):3546-56.
141. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000 Dec 23-30;356(9248):2144-8.
142. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 Mar 5;360(10):973-84.
143. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5;360(10):985-93.
144. Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
145. Zhou G, Ma Y, Jia P, Guan Q, Uzonna JE, Peng Z. Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice. Vaccine. 2010 Feb 17;28(7):1838-46.
146. Norman P. DP(2) receptor antagonists in development. Expert Opin Investig Drugs. 2010;19(8):947-61.
147. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2011 Jul 15. doi: 10.1111/j.1365-2222.2011.03813.x.[Epub ahead of print].
148. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med. 2005;11:1173-9.
149. Knobloch J, Sibbing B, Jungck D, et al. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2010;335(3):788-98.
150. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135:173-80.
151. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:253-68.
152. Bara I, Ozier A, Tunon de Lara JM, Marthan R, Berger P. Pathophysiology of bronchial smooth muscle remodelling in asthma. Eur Respir J. 2010;36(5):1174-84.
153. Laurent GJ, McAnulty RJ, Hill M, Chambers R. Escape from the matrix: multiple mechanisms for fi broblast activation in pulmonary fi brosis. Proc Am Thorac Soc. 2008;5:311-15.
154. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;138(5):1202-12.
155. Xie J, Poda GI, Hu Y, et al. Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship. Bioorg Med Chem. 2011;19(3):1242-55.
156. Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011;139(6):1470-9.
157. Sommers CD, Thompson JM, Guzova JA, et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther. 2009 Aug;330(2):377-88.
158. Larocca NE, Moreno D, Garmendia JV, De Sanctis JB. Inhibitors of Phosphoinositol 3 Kinase and NFkB for the Treatment of Chronic Obstructive Pulmonary Disease. Recent Pat Inflamm Allergy Drug Discov. 2011 Aug 9.
159. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11(7):577-84.